These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24943810)

  • 41. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
    Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
    Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
    Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
    Front Immunol; 2021; 12():652160. PubMed ID: 33859645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
    Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
    Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
    [No Abstract]   [Full Text] [Related]  

  • 45. Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536.
    Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Rosas-Murrieta NH; Millán-Pérez Peña L
    Expert Opin Ther Pat; 2020 Feb; 30(2):83-86. PubMed ID: 31874056
    [No Abstract]   [Full Text] [Related]  

  • 46. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
    Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
    Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
    Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
    Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
    Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.
    Wang Y; Zhuang Q; Zhou S; Hu Z; Lan R
    J Huazhong Univ Sci Technolog Med Sci; 2009 Feb; 29(1):77-9. PubMed ID: 19224168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
    Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L
    Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and Tretinoin.
    Górski GK; McMorrow LE; Donaldson MH
    In Vitro Cell Dev Biol; 1993 Mar; 29A(3 Pt 1):189-91. PubMed ID: 8463182
    [No Abstract]   [Full Text] [Related]  

  • 55. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nicotinamide N-oxides as CXCR2 antagonists.
    Cutshall NS; Ursino R; Kucera KA; Latham J; Ihle NC
    Bioorg Med Chem Lett; 2001 Jul; 11(14):1951-4. PubMed ID: 11459668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.